Understanding divergent trial results of adjuvant CDK4/6 inhibitors for early stage breast cancer

被引：8
|
作者：
Cunningham, Niamh C. [1 ]
Turner, Nicholas C. [1 ,2 ,3 ]
机构：
[1] Royal Marsden Hosp, Breast Unit, London, England
[2] Royal Marsden Hosp, Ralph Lauren Ctr Breast Canc Res, London, England
[3] Inst Canc Res, Breast Canc Now Res Ctr, London, England
来源：
CANCER CELL | 2021年 / 39卷 / 03期
关键词：
ENDOCRINE THERAPY;
D O I：
10.1016/j.ccell.2021.02.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CDK4/6 inhibitors have transformed the treatment of metastatic estrogen-receptor-positive HER2-negative breast cancer, with efficacy found consistently for three different inhibitors. Recent adjuvant trials of CDK4/6 inhibitors in early stage breast cancer have produced discordant results, shedding light on their clinical utility and future trial design.
引用
收藏
页码：307 / 309
页数：3
相关论文
共 50 条
  • [31] Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
    George, Mridula A.
    Qureshi, Sadaf
    Omene, Coral
    Toppmeyer, Deborah L.
    Ganesan, Shridar
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [32] Cardiac complications of CDK4/6 inhibitors for breast cancer.
    Master, Samip R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
    Piezzo, Michela
    Cocco, Stefania
    Caputo, Roberta
    Cianniello, Daniela
    Di Gioia, Germira
    Di Lauro, Vincenzo
    Fusco, Giuseppina
    Martinelli, Claudia
    Nuzzo, Francesco
    Pensabene, Matilde
    De Laurentiis, Michelino
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (18) : 1 - 23
  • [34] An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer
    Robert, Marie
    Frenel, Jean-Sebastien
    Bourbouloux, Emmanuelle
    Rigaud, Dominique Berton
    Patsouris, Anne
    Augereau, Paule
    Gourmelon, Carole
    Campone, Mario
    [J]. DRUGS, 2018, 78 (13) : 1353 - 1362
  • [35] CDK4/6 inhibition in early and metastatic breast cancer: A review
    de Groot, A. F.
    Kuijpers, C. J.
    Kroep, J. R.
    [J]. CANCER TREATMENT REVIEWS, 2017, 60 : 130 - 138
  • [36] CDK4/6 inhibitors
    不详
    [J]. CHEMICAL & ENGINEERING NEWS, 2016, : 30 - 31
  • [37] First clinical experience with CDK4/6 inhibitors in breast cancer therapy
    Cobec, Ionut Marcel
    Moleriu, Lavinia
    Moatar, Aurica Elisabeta
    Rempen, Andreas
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (05)
  • [38] SBRT with CDK4/6 inhibitors for oligorecurrent/oligoprogressive breast cancer patients
    Ippolito, E.
    Onorati, E.
    Greco, C.
    Fiore, M.
    Silipigni, S.
    Matteucci, P.
    Cerasani, L.
    Carrafiello, S.
    Palumbo, V.
    Ramella, S.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1298 - S1298
  • [39] Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
    Barroso-Sousa, Romualdo
    Shapiro, Geoffrey I.
    Tolaney, Sara M.
    [J]. BREAST CARE, 2016, 11 (03) : 167 - 173
  • [40] Recent advances of highly selective CDK4/6 inhibitors in breast cancer
    Hanxiao Xu
    Shengnan Yu
    Qian Liu
    Xun Yuan
    Sridhar Mani
    Richard G. Pestell
    Kongming Wu
    [J]. Journal of Hematology & Oncology, 10
12345